- Home
- CDTX vs ZNTL Comparison
CDTX vs ZNTL Comparison
Compare CDTX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- ZNTL
- Stock Information
- Founded
- CDTX 2012
- ZNTL 2014
- Country
- CDTX United States
- ZNTL United States
- Employees
- CDTX N/A
- ZNTL N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CDTX Health Care
- ZNTL Health Care
- Exchange
- CDTX Nasdaq
- ZNTL Nasdaq
- Market Cap
- CDTX 242.5M
- ZNTL 227.0M
- IPO Year
- CDTX 2015
- ZNTL 2020
- Fundamental
- Price
- CDTX $20.53
- ZNTL $2.92
- Analyst Decision
- CDTX Strong Buy
- ZNTL Buy
- Analyst Count
- CDTX 6
- ZNTL 8
- Target Price
- CDTX $32.20
- ZNTL $10.50
- AVG Volume (30 Days)
- CDTX 86.5K
- ZNTL 997.7K
- Earning Date
- CDTX 11-07-2024
- ZNTL 11-12-2024
- Dividend Yield
- CDTX N/A
- ZNTL N/A
- EPS Growth
- CDTX N/A
- ZNTL N/A
- EPS
- CDTX N/A
- ZNTL N/A
- Revenue
- CDTX $44,653,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- CDTX N/A
- ZNTL N/A
- Revenue Next Year
- CDTX N/A
- ZNTL N/A
- P/E Ratio
- CDTX N/A
- ZNTL N/A
- Revenue Growth
- CDTX 44.48
- ZNTL N/A
- 52 Week Low
- CDTX $10.00
- ZNTL $2.66
- 52 Week High
- CDTX $24.99
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- CDTX 55.06
- ZNTL 38.90
- Support Level
- CDTX $21.15
- ZNTL $3.01
- Resistance Level
- CDTX $24.99
- ZNTL $4.00
- Average True Range (ATR)
- CDTX 2.10
- ZNTL 0.27
- MACD
- CDTX -0.15
- ZNTL -0.07
- Stochastic Oscillator
- CDTX 41.16
- ZNTL 8.44
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.